Johnson & Johnson $JNJ Shares Sold by Robertson Stephens Wealth Management LLC

Robertson Stephens Wealth Management LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 4.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 24,742 shares of the company’s stock after selling 1,206 shares during the quarter. Robertson Stephens Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,779,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Cascade Investment Group Inc. increased its stake in Johnson & Johnson by 56.1% during the second quarter. Cascade Investment Group Inc. now owns 4,085 shares of the company’s stock worth $624,000 after acquiring an additional 1,468 shares during the last quarter. Monument Capital Management increased its stake in Johnson & Johnson by 44.3% during the second quarter. Monument Capital Management now owns 6,012 shares of the company’s stock worth $918,000 after acquiring an additional 1,847 shares during the last quarter. Cyndeo Wealth Partners LLC increased its stake in Johnson & Johnson by 2.8% during the second quarter. Cyndeo Wealth Partners LLC now owns 63,594 shares of the company’s stock worth $9,714,000 after acquiring an additional 1,753 shares during the last quarter. 3Chopt Investment Partners LLC increased its stake in Johnson & Johnson by 1.5% during the second quarter. 3Chopt Investment Partners LLC now owns 21,999 shares of the company’s stock worth $3,360,000 after acquiring an additional 330 shares during the last quarter. Finally, Morton Brown Family Wealth LLC increased its stake in Johnson & Johnson by 2,715.3% during the second quarter. Morton Brown Family Wealth LLC now owns 2,027 shares of the company’s stock worth $310,000 after acquiring an additional 1,955 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. HSBC upped their price target on Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Sanford C. Bernstein upped their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $192.94.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ opened at $190.66 on Monday. The company has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $192.10. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a 50-day moving average price of $178.48 and a 200 day moving average price of $163.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.